Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it presented updated preliminary Phase I data on TG4050, its individualized neoantigen cancer vaccine, in a poster session at the American Society of Clinical Oncology annual meeting.
June 6, 2022
· 11 min read